LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study)

NCT06939322 | Recruiting

• 2 other identifiers: 49RC25_00352025-A00237-42
• Study Type: interventional
• Target: 320
• Locations: 1 country
• Sites: 1

Brief Summary

Childhood cancer survivors represent a high-risk population that requires risk-based follow-up. Follow-up recommendations have been harmonized. Education and information practices regarding follow-up recommendations should be personalized, to ensure understanding by all survivors, including those with neurocognitive disorders. Individualized follow-up is necessary to detect complications that may increase morbidity and decrease quality of life, or even increase the risk of early mortality. In France, the LOG-AFTER software was developed in 2017 by university hospital of Angers and Epiconcept (approved health data host). The main differences with the European procedure concern radiotherapy information, the link with the General practitioner (GP), and the possible addition of information and/or access to therapeutic education in a video format. Indeed, there is the possibility of creating an GP account allowing to receive notifications concerning the follow-up of his patient to be scheduled, to have access to his file summary and his personalized follow-up plan, various information and blank prescription models. LOG-I is a study of the impact of the LOG-AFTER software for the "patient/GP" couple on adherence to follow-up recommendations. LOG-I is interested in all former patients with at least 3 recommendations in their personalized follow-up plan, taking into account the specific population of patients cured of a brain tumor.

Conditions

Pediatric Cancer; Cancer Survivor; Hemato-oncologic Patients

Keywords

pediatry; oncology; hematology; radiotherapy; survivorship; preventive care

Outcome Measures

Primary Outcomes (1)

• PPAC adherence

  Evaluate the impact of LOG-AFTER on former patients' adherence to the Personalized After-Cancer Plan (PPAC) for those with at least 3 follow-up examinations. (Adherence = For a number of screens between three and six (3-6), adherence is considered adequate if all screens or all but one screen have been completed. For seven or more screens (\>7), it is considered adequate if all screens or all but two screens have been completed)

  3 years

Secondary Outcomes (8)

• PPAC adherence for survivors of brain tumor treated, at least, with radiotherapy

  3 years

• Health status

  3 years

• PPAC adherence for new cancer survivors partients starting long term follow-up

  3 years

• PPAC adherence for cancer survivors already involved in long term follow-up before the study

  3 years

• Describe the patient satisfaction

  3 years

Study Arms (2)

Use of the software Log-AFTER

EXPERIMENTAL

Patients are monitored with the help of LOG-AFTER software. Patients are advised to report the completion of the examinations (date and overall conclusion), which allows the software to function properly. The GP is also advised to report any consultations his patient has had with him and to update the date of the examinations if his patient has not done so.

Other: Use of the Log-AFTER software

WITHOUT Log-After

NO INTERVENTION

Patients are monitored without the LOG-AFTER software.

Interventions

Use of the Log-AFTER software OTHER

The LOG-AFTER software is used for long-term follow-up care after cancer to empower patients

Use of the software Log-AFTER

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Previously treated for cancer or malignant hematological pathology before the age of 25
• Without residual disease or with a stable disease without treatment for 5 years or more
• Owning a computer, smartphone or equivalent I-Pad/tablet with internet access
• Having signed the consent (or their parents if the patient is a minor, or a third party if necessary)
• Having 3 or more recommended screenings in their survivorship care plan

You may not qualify if:

• Patient who has relapsed or developed a second cancer with a post-treatment delay \< 5 years
• Patient not covered by a health insurance
• Patient subject to a legal protection measure, patient deprived of liberty by judicial or administrative decision, patient subject to psychiatric care under duress

Sponsors & Collaborators

• University Hospital, Angers: lead
• National Cancer Institute, France: collaborator

Study Sites (1)

University Hospital of Angers

Angers, Maine Et Loire, 49933, France

RECRUITING

Related Links

• Related Info

MeSH Terms

Conditions

Neoplasms

Study Officials

• Charlotte DEMOOR-GOLDSCHMIDT, Dr

  University Hospital of Angers

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sandra MERZEAU

CONTACT

(+33)2 41 35 59 70; samerzeau@chu-angers.fr

Pascal VEILLON

CONTACT

(+33)2 41 35 49 59; paveillon@chu-angers.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Model Details: Randomization WITH vs WITHOUT use of the software LOG-AFTER designed for survivorship

Study Record Dates

• First Submitted: March 6, 2025
• First Posted: April 22, 2025
• Study Start: June 6, 2025
• Primary Completion (Estimated): November 6, 2026
• Study Completion (Estimated): June 6, 2030
• Last Updated: July 2, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)